I provide independent and original analysis, pricing metrics and recommendations for the stem, cell, gene and regenerative therapy equities.

Histogenics (HSGX), ups enrollment numbers

October 24, 2016

  HSGX had enrolled 183, of the 245 patients required to complete enrollment of its ongoing NeoCart P3 clinical trial.  HSGX is DOWN -$0.06 to $2.71 – BUY on weakness  

Aduro Biotech (ADRO) reports Clinical Hold to pause enrollment in LADD trials

October 24, 2016

Stock drops -7.55% or -$0.93 to $11.32 ... protocal changes take time to implement, SELL  

Northwest Biotherapeutics (NWBO) proposes 14 M share RDO at $0.38 to raise $5 M

October 21, 2016

NWBO is DOWN -$0.09 ($0.45) having closed at $0.54 - "stayin alive" money  

Roll Call

The process of calling out our grading of covered companies to rank and review the facts in evidence together with analysis, opinion and objective recommendation.